Moleculin Announces Reverse Stock Split

Moleculin Biotech, Inc. , (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that it filed an amendment to its amended and restated certificate of incorporation with the Secretary of State of the State of Delaware to effect a 1-for-20 reverse stock split of its common stock. The reverse stock split will take effect at 12:01 am (Eastern Time) on October 20, 2026, and the Company’s common stock will open for trading on The Nasdaq Capital Market on October 20, 2026 on a post-split basis, under the existing ticker symbol “MBRX” but with a new CUSIP number 60855D 507.